Optimum Investment Advisors trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 22.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,282 shares of the medical equipment provider’s stock after selling 7,750 shares during the period. Optimum Investment Advisors’ holdings in Hologic were worth $964,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. boosted its stake in Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after buying an additional 1,200,825 shares during the last quarter. Parnassus Investments CA acquired a new stake in Hologic in the 3rd quarter worth about $277,062,000. Capital World Investors acquired a new stake in Hologic in the 2nd quarter worth about $312,441,000. Victory Capital Management Inc. boosted its stake in Hologic by 16.8% in the 3rd quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock worth $214,885,000 after buying an additional 844,426 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Hologic by 2.5% in the 2nd quarter. Northern Trust Corp now owns 3,277,739 shares of the medical equipment provider’s stock worth $148,743,000 after buying an additional 79,697 shares during the last quarter. 98.08% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on HOLX. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price target on the stock in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $48.00 price target (up from $46.00) on shares of Hologic in a research note on Tuesday, December 5th. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and raised their price objective for the stock from $45.00 to $50.00 in a report on Friday, December 8th. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $45.00 price objective (down from $48.00) on shares of Hologic in a report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Hologic presently has a consensus rating of “Buy” and a consensus price target of $47.86.

Hologic, Inc. (NASDAQ HOLX) opened at $42.96 on Friday. The company has a market capitalization of $12,011.53, a PE ratio of 21.57, a PEG ratio of 2.11 and a beta of 0.95. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. The business had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted $0.52 EPS. equities research analysts anticipate that Hologic, Inc. will post 2.12 earnings per share for the current year.

In related news, Director Lawrence M. Levy sold 7,138 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $37.38, for a total transaction of $266,818.44. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,833 shares of company stock worth $1,107,270. Company insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/15/hologic-inc-holx-shares-sold-by-optimum-investment-advisors.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.